Imunon, Inc. cotiza a 1.07 USD y tiene una capitalización bursátil de $6M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the IND-enab…
| Periodo | 2026-05 | 2026-03 | 2025-11 | 2025-08 |
|---|---|---|---|---|
| Real | $-0.84 | $-1.30 | $-1.16 | $-1.87 |
| Estimado | $-1.28 | $-1.82 | $-1.82 | $-4.34 |
| Sorpresa | +34.4% | +28.6% | +36.3% | +56.9% |
| Métrica | IMNN | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -205.3% | -40.4% | -164.9% |
| ROA | -118.0% | -32.0% | -85.9% |
| Current Ratio | 2.32 | 2.84 | -0.52 |
| Debt / Equity | — | 0.28 | — |